Form 8-K - Current report:
SEC Accession No. 0001193125-26-337944
Filing Date
2026-08-06
Accepted
2026-08-06 16:05:18
Documents
10
Period of Report
2026-08-06
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K inab-20260806.htm   iXBRL 8-K 51171
2 EX-99.1 inab-ex99_1.htm EX-99.1 243105
  Complete submission text file 0001193125-26-337944.txt   418542

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT inab-20260806.xsd EX-101.SCH 25964
13 EXTRACTED XBRL INSTANCE DOCUMENT inab-20260806_htm.xml XML 4926
Mailing Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118
Business Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118 (646) 600-6438
IN8BIO, INC. (Filer) CIK: 0001740279 (see all company filings)

EIN.: 825462585 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39692 | Film No.: 261248838
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)